Orthofix Medical (NASDAQ:OFIX) CFO Sells $70,073.74 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,873 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total value of $70,073.74. Following the completion of the transaction, the chief financial officer directly owned 58,039 shares of the company’s stock, valued at $834,600.82. The trade was a 7.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Orthofix Medical Stock Performance

Shares of NASDAQ:OFIX traded up $0.21 during trading on Wednesday, hitting $13.85. 162,693 shares of the stock traded hands, compared to its average volume of 213,984. The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39. The company has a fifty day moving average price of $15.30 and a two-hundred day moving average price of $14.36. Orthofix Medical Inc. has a 52-week low of $10.24 and a 52-week high of $20.48. The company has a market cap of $548.46 million, a price-to-earnings ratio of -4.57 and a beta of 0.79.

Institutional Trading of Orthofix Medical

Several large investors have recently bought and sold shares of the business. Diversified Trust Co. purchased a new position in shares of Orthofix Medical during the 4th quarter worth approximately $159,000. JPMorgan Chase & Co. lifted its stake in Orthofix Medical by 33.3% during the third quarter. JPMorgan Chase & Co. now owns 258,035 shares of the medical device company’s stock worth $3,778,000 after purchasing an additional 64,486 shares during the last quarter. Tudor Investment Corp ET AL boosted its holdings in Orthofix Medical by 268.8% in the third quarter. Tudor Investment Corp ET AL now owns 217,044 shares of the medical device company’s stock valued at $3,178,000 after purchasing an additional 158,197 shares in the last quarter. Millennium Management LLC increased its stake in Orthofix Medical by 86.6% in the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock valued at $21,605,000 after purchasing an additional 684,850 shares during the last quarter. Finally, Juniper Investment Company LLC increased its stake in Orthofix Medical by 15.3% in the third quarter. Juniper Investment Company LLC now owns 2,847,055 shares of the medical device company’s stock valued at $41,681,000 after purchasing an additional 377,729 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on OFIX. Barrington Research boosted their price objective on Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a report on Wednesday, October 8th. Finally, Stifel Nicolaus began coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.